Lek receives a special award on the 15th anniversary of the Family Friendly Company certificate
- On this year's 15th anniversary of the Family Friendly Company certificate, Ekvilib Institute, a non-profit and independent organization, the coordinator of the certificate, presented Lek with a special award.
- Lek is one of the first generation of recipients of the certificate and has held it since 2007. It is also a four-time winner of the full Family Friendly Company certificate.
- For years, Lek has been committed to creating a supportive and high-quality working environment where associates can reach their full potential.
For many years, Lek has been committed to caring for its associates and to creating a working environment in which they feel comfortable and which enables them to effectively balance their professional and private lives. As a long-standing holder of the Family Friendly Company certificate – the company has been a recipient since the certificate's inception in 2007 – Lek has time and again proven its commitment to creating a work environment that is friendly to associates and their families.
On the 15th anniversary of the Family Friendly Company certificate, a special award ceremony was held at a gala event organized by the Ekvilib Institute to honor all companies representing the first generation of certificate recipients. "We are delighted to receive this recognition, which confirms our commitment to the well-being of our associates. We design our working environment with their wishes, needs and well-being in mind. This was particularly evident during the epidemic, when we took a series of measures such as remote working, organized childcare and extra days of leave for parents of school-age children who attended school remotely. As a company that puts its associates first, we strive to make it as easy as possible for our associates to reconcile work and family life," said Marjan Novak, Member of the Board of Management of Lek d.d. and Workers' Director, upon receiving the special award.
Lek started introducing and promoting programs to boost mental and physical well-being at work, flexible working and remote working several years ago. The Choice with Responsibility working model was fully implemented recently, allowing associates to choose how, where and when they do their work, depending on the nature of their work. "With the new way of working, we have done away with the old hierarchical structures and introduced an agile culture that unbosses our associates while giving them the freedom to balance their work and private lives," added Marjan Novak.
Novartis is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc. and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high-quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Operations, Global Drug Development and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 3 billion since 2003.
About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
This press release contains statements and forecasts of future business operations.The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
For further information, please contact:
Gregor Makuc
Communication & External Engagement
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43
gregor.makuc@sandoz.com
Photo for print
Previous press releases
Contact us
Gregor Makuc
T: +386 1 580 22 43
info.lek@sandoz.com